Cell-Based Vaccine Compositions and Methods of Use
Patent Number: WO2017136633A9
Executive Summary:
General Description:
Antigen presenting cells can be administered and can trigger anti-tumor immune responses to treat or cure cancer. Dendritic cells are commonly used to trigger anti-tumor immune responses and to create cell-based vaccines. The inventors discovered that, against prior dogma, monocytes and neutrophils are significantly better at triggering anti-tumor immune responses, suggesting that cell-based vaccines should be composed of monocytes and neutrophils instead of dendritic cells. The inventors provide methods and kits for creating these novel monocyte and neutrophil-based cell vaccines.
Scientific Progress:
Administration of novel cell-based vaccines almost completely eradicates melanoma tumors in mice.
Future Directions:
Strengths:
Weaknesses:
Patent Status:
Legal Status: Pending
Publication PMID: 25762141
Publication:
Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19;519(7543):366-9.
Inventor Bio: Michael D. Gunn
https://scholars.duke.edu/person/michael.gunn
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Pending
- Patent Link: https://patents.google.com/patent/WO2017136633A9
- Research Institute: Duke University
- Disease Focus: Gliomas, including Glioblastoma
- Basis of Invention: Novel cell-based vaccine for stimulating an anti-tumor immune response in mice and humans
- How it works: The cell-based vaccine compositions are made by selecting monocytes and/or neutrophils from a sample from a subject. The selected monocytes and/or neutrophils are then contacted with an antigenic polypeptide or a polynucleotide encoding the antigenic polypeptide in order to load the cells with the antigenic polypeptide or polynucleotide encoding the antigenic polypeptide. More than one antigenic polypeptide or polynucleotide may be loaded into the cells. Finally, the loaded cells are collected to prepare the vaccine composition. The resultant vaccine composition can be administered to the subject to treat the disease or condition. Mammals and in particular humans represent suitable subjects though any animal with an immune system comprising T cells can be used in the methods.
- Lead Challenge Inventor: Michael D. Gunn
- Development Stage: Preclinical
- Novelty:
- Monocyte and neutrophil-based compositions to stimulate a stronger anti-tumor immune response compared to the commonly used dendritic cell-based compositions
- Clinical Applications:
- Use as a cell-based vaccine against cancer or infectious disease
General Description:
Antigen presenting cells can be administered and can trigger anti-tumor immune responses to treat or cure cancer. Dendritic cells are commonly used to trigger anti-tumor immune responses and to create cell-based vaccines. The inventors discovered that, against prior dogma, monocytes and neutrophils are significantly better at triggering anti-tumor immune responses, suggesting that cell-based vaccines should be composed of monocytes and neutrophils instead of dendritic cells. The inventors provide methods and kits for creating these novel monocyte and neutrophil-based cell vaccines.
Scientific Progress:
Administration of novel cell-based vaccines almost completely eradicates melanoma tumors in mice.
Future Directions:
- Clinical validation in humans
Strengths:
- This novel monocyte and neutrophil-based vaccine triggers a significantly greater anti-tumor immune response compared to the commonly used dendritic cell-based vaccines and adjuvants
- This method for creating cell-based vaccines is simpler, faster, and cheaper than the methods for making other cell-based vaccines
Weaknesses:
- Not yet tested in humans
Patent Status:
Legal Status: Pending
- Priority date: 2016-02-04
- Filing date: 2017-02-03
- Publication date: 2018-01-04
Publication PMID: 25762141
Publication:
Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19;519(7543):366-9.
Inventor Bio: Michael D. Gunn
https://scholars.duke.edu/person/michael.gunn
